RxDoctor Payments Data

Luke Chesney, MD

Family Medicine · Knoxville, TNNPI 1225292162

Payments from drug & device makers

$9,552in general payments, 2019–2025

Across 653 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$961
  • GSK$802
  • Novo Nordisk$726
  • Boehringer Ingelheim$560
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,546100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,552 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$132,141
Medicare patients
316
Services billed
3,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$83,669
EliquisApixaban53$66,942
OzempicSemaglutide37$64,231
JardianceEmpagliflozin51$58,541
JanuviaSitagliptin Phosphate26$39,684
XareltoRivaroxaban25$36,263
TrulicityDulaglutide20$33,870
RybelsusSemaglutide16$30,487
FarxigaDapagliflozin Propanediol19$26,040
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,863
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$13,667
Tresiba Flextouch U-200Insulin Degludec13$12,107
Spiriva RespimatTiotropium Bromide13$11,584
MyrbetriqMirabegron18$8,376
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$7,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$961$117,53976 claims
Novo NordiskOzempic, Rybelsus$726$94,71853 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$560$78,08681 claims
PfizerEliquis, Premarin$1,229$71,67067 claims
MerckJanuvia$222$39,68426 claims
Johnson & JohnsonXarelto$118$36,26325 claims
AstraZenecaFarxiga, Symbicort$358$33,19841 claims
GSKTrelegy Ellipta$802$13,86314 claims
Astellas Pharma US IncMyrbetriq$67$8,37618 claims
AbbVieSynthroid$1,356$1,59315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →